Paxlovid Won't Cut Odds for Long COVID: Study

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 8, 2024.

By Dennis Thompson HealthDay Reporter

MONDAY, Jan. 8, 2024 -- Paxlovid might help shorten and diminish a COVID infection, but the antiviral doesn’t reduce the risk of developing long COVID, a new study shows.

About 16% of COVID patients treated with Paxlovid wound up with long COVID symptoms, compared to 14% of those not given the oral medication, researchers found.

“Our finding that Paxlovid treatment during acute infection is not associated with lower odds of long COVID surprised us, but it is consistent with two other rigorously conducted studies finding no difference in post-COVID conditions between 4 and 6 months after infection,” said lead author Dr. Matthew Durstenfeld, an assistant professor of medicine at the University of California, San Francisco.

Paxlovid is recommended for treating people at high risk for severe COVID infection, to ease symptoms and keep them out of the hospital.

But there’s been some debate regarding whether the drug could prevent long COVID, in which symptoms caused by the initial infection can last for weeks, months or even years.

For this study, Durstenfeld and his colleagues followed up on COVID patients treated between March and August 2022, to see if they had developed long COVID.

Not only did Paxlovid not prevent long COVID, but the researchers found those who took the drug went on to have as many long COVID symptoms as those who didn’t.

The most common long COVID symptoms included fatigue, shortness of breath, confusion, headache and altered taste and smell.

A small percentage of people went on to develop severe long COVID, and again those who received Paxlovid were just as likely as those who didn’t to have long-term severe symptoms.

Researchers also found that more people than expected experienced a “rebound” after taking Paxlovid, with their COVID infection roaring back after it had appeared to go away.

About 21% of people who improved while taking Paxlovid wound up reporting rebound symptoms, and about 26% re-tested positive for COVID after testing negative and completing their treatment.

However, this rebound didn’t appear to make patients more inclined to develop long COVID. About 11% of rebound patients reported long COVID symptoms, compared with 8% of those who didn’t rebound.

“We found a higher proportion with clinical rebound than previously reported, but did not identify an effect of post-treatment rebound on long COVID symptoms,” Durstenfeld said in a university news release.

The new study was published Jan. 4 in the Journal of Medical Virology.

Sources

  • University of California, San Francisco, news release, Jan. 4, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-01-09 02:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords